These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 8855818)

  • 41. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
    Colleluori G; Aguirre L; Napoli N; Qualls C; Villareal DT; Armamento-Villareal R
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3058-e3068. PubMed ID: 33735389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone.
    Herbst KL; Anawalt BD; Amory JK; Matsumoto AM; Bremner WJ
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1167-73. PubMed ID: 12629101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels.
    Bhasin S; Storer TW; Asbel-Sethi N; Kilbourne A; Hays R; Sinha-Hikim I; Shen R; Arver S; Beall G
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3155-62. PubMed ID: 9745419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.
    Leifke E; Körner HC; Link TM; Behre HM; Peters PE; Nieschlag E
    Eur J Endocrinol; 1998 Jan; 138(1):51-8. PubMed ID: 9461316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Fall PM; Albertsen PC; Dowsett RD; Trahiotis M; Zimmerman J; Ohannessian C; Raisz LG
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4907-13. PubMed ID: 12414849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.
    Uebelhart B; Herrmann F; Pavo I; Draper MW; Rizzoli R
    J Bone Miner Res; 2004 Sep; 19(9):1518-24. PubMed ID: 15312253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI).
    Van Caenegem E; Wierckx K; Taes Y; Schreiner T; Vandewalle S; Toye K; Lapauw B; Kaufman JM; T'Sjoen G
    Eur J Endocrinol; 2015 Feb; 172(2):163-71. PubMed ID: 25550352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
    Guo CY; Jones TH; Eastell R
    J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transdermal testosterone therapy in the treatment of male hypogonadism.
    Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
    J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
    Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
    Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
    Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment.
    De Rosa M; Paesano L; Nuzzo V; Zarrilli S; Del Puente A; Oriente P; Lupoli G
    J Endocrinol Invest; 2001 Apr; 24(4):246-52. PubMed ID: 11383911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial trial of slow-release testosterone microspheres in hypogonadal men.
    Burris AS; Ewing LL; Sherins RJ
    Fertil Steril; 1988 Sep; 50(3):493-7. PubMed ID: 3410101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.